Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vernalis, Cancer Research Technology Ltd., The Institute of Cancer Research deal

VER exercised its option, under a 2002 deal, to an

Read the full 101 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE